Advance Prefill Able Plastic
Syringe Technology: BD To Partner Mitsubishi Chemical Partner For Innovation
The companies will seek to expand applications for Oxycaptbranded plastic
syringes for novel pharmaceutical compounds.
Global medical technology company BD (Becton, Dickinson, and Co.) and Mitsubishi
Gas Chemical Co. Inc. (MCG) recently signed a letter of intent to discuss a
partnership to explore new ways to advance prefillable syringe technology for
biologic drug delivery. Specifically, the agreement states that they will
investigate further development of Oxycapt, an innovation from MGC that
integrates what it calls the best of plastic and glass for plastic syringes.
Together, the companies will look into applying Oxycapt technology to the next
generation of prefillable syringes for advanced biologic pharmaceuticals.
BD said in the announcement that it has been working for decades to optimize the
performance of prefillable syringes, which improves the delivery of drugs and
vaccines. It is the world leader in supplying prefillable syringes to the
biopharmaceutical industry, with more than 70% of the top 100 biopharmaceutical
companies reportedly using its devices. BD manufactures both glass and plastic
syringes to meet the unique needs of drugs.
“The biopharmaceutical industry continues to rely on prefillable syringes for
the effective, reliable, and consistent administration of medications,” said
Bruno Baney, Vice President, R&D, BD Medical – Pharmaceutical Systems. “As our
customers continue to grow their drug pipelines, we are constantly exploring
solutions to deliver newer compounds in robust, stable, and ready-toadminister
formats. This agreement will further help us do so, as MGC’s experience in
providing technical innovation in materials will serve as a strategic complement
to our legacy of supporting the latest innovations in drug delivery for our
The Oxycapt multilayer structure is applied on silicon-free plastic syringe
barrels that provide breakage resistance, an oxygen and vapor barrier, low
protein adsorption, low extractables, and high UV barrier and pH stability, said
“Since launching Oxycapt, more and more pharmaceutical companies have been
interested in applying it to their biologics or regenerative medicines such as
gene/cell therapies,” said Ko Kedo, an executive officer of MGC’s R&D division.
“As we have looked for a strategic partner to enhance presence of Oxycapt in the
pharmaceutical industry, the partnership with BD will be an ideal solution for
MGC. We believe this agreement will make it possible for customers to choose the
best syringes for their
Some pharmaceutical compounds based on mRNA, viral vector, or innovative
antibody technologies may face challenges related to stability or integration
with glass-based prefillable syringes, said BD. Through this partnership, BD and
MGC will explore practical solutions for delivering newer biologic compounds.
Both companies noted that they share a commitment to advancing sustainability
and reducing their carbon footprints.
(Ref : https://www.plasticstoday.com/medical/bd-mitsubishichemical-partner-advance-prefillable-syringe-technology,
Jun 13, 2022)